Notably, we observed a significant increase in glycosylation of PD-L1 in BC (Fig. 3C), consistent with recent findings that monoclonal targeting of glycosylated PD-L1 could offer a promising therapeutic approach for TN BC patients [41]. Here, CD274 is linked to breast cancer.